- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Global Cancer Biomarkers Market to Reach $42.0 Billion by 2029
Cancer Biomarkers Market by Profiling Technology, Cancer Type, Product, Application, End-user, and Region – Global Forecast to 2029
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
According to MarketsandMarkets™, the global cancer biomarkers market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period. The market is driven by the increasing incidence of cancer, growing investments in research and development of cancer biomarkers, and the extensive use of these biomarkers for diagnosis, drug discovery, and development.
Why it matters
The growth of the cancer biomarkers market is crucial as it enables early detection, diagnosis, and monitoring of various types of cancer, which can significantly improve patient outcomes. The development of advanced biomarker profiling technologies and the increasing focus on personalized medicine are also contributing to the market's expansion.
The details
The cancer biomarkers market is segmented based on profiling technology (omics and imaging), cancer type (lung, breast, leukemia, melanoma, colorectal), product (instruments, consumables, bioinformatics software), application (risk assessment, prognostics, diagnostics, R&D), and end-user. The omics technology segment dominated the market in 2023 due to its high-throughput nature in cancer biomarker discovery and diagnosis. The breast cancer segment held the largest market share in 2023, and the instruments segment led the product category due to the continuous need for cancer detection and improvements in instrument technology.
- The global cancer biomarkers market is projected to reach USD 42.0 billion by 2029.
- The market is expected to grow at a CAGR of 11.3% during the forecast period from 2024 to 2029.
The players
Thermo Fisher Scientific, Inc.
A leading provider of instruments, consumables, and bioinformatics software for cancer biomarker research and diagnostics.
QIAGEN N.V.
A global provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research.
Illumina, Inc.
A leading developer of next-generation sequencing technologies and bioinformatics solutions for cancer biomarker research and diagnostics.
Bio-Rad Laboratories, Inc.
A manufacturer of a wide range of instruments and consumables for cancer biomarker detection and analysis.
Abbott Laboratories
A diversified healthcare company that develops and markets a range of cancer diagnostic tests and biomarkers.
What’s next
The market is expected to continue growing as companies in the cancer biomarkers space focus on developing new and improved technologies, expanding their product portfolios, and collaborating with research institutions and healthcare providers to drive further advancements in cancer diagnostics and personalized medicine.
The takeaway
The global cancer biomarkers market is poised for significant growth in the coming years, driven by the increasing incidence of cancer, the need for early detection and diagnosis, and the ongoing advancements in biomarker profiling technologies. This market presents lucrative opportunities for companies and researchers working to improve cancer care and patient outcomes.
